INTRODUCTION
============

RAS proteins function as a signal relay molecules that can transmit receptor activation by external stimuli such as growth hormones or environmental stress to downstream effectors leading to major cellular responses such as proliferation, survival and differentiation ([@b7-molce-42-441]). Somatic gain-of-function mutations in *RAS* genes are found in one third of human cancers ([@b43-molce-42-441]) and thus RAS pathway has been extensively studied in the context of oncogenesis. Since the discovery of *NF1* mutations in neurofibromatosis 1, germline mutations in the components of RAS signaling pathway also have been found in some congenital disorders such as Noonan, LEOPARD (Lentigines, Electrocardiographic conduction abnormalities, Ocular hypertelorism, Pulmonic stenosis, Abnormal genitalia, Retardation of growth, Deafness), Cardio-facio-cutaneous and Costello syndromes suggesting that aberrant RAS signaling may contribute to the pathogenesis of developmental disorders as well. Genes mutated in these diseases include *HRAS*, *KRAS*, *BRAF*, *NF1*, *SOS1*, *PTPN11* (which encodes SHP2), and *MEK* ([Fig. 1C](#f1-molce-42-441){ref-type="fig"}). The developmental disorders associated with RAS pathway mutations, collectively known as RASopathies, share clinical features such as craniofacial, cardiac, cutaneous, musculoskeletal and ocular abnormalities. Neurological abnormalities including neurocognitive impairment, hypotonia, macrocephaly, and seizure are also present to varying degrees ([@b54-molce-42-441]).

RAS proteins, *KRAS*, *HRAS*, and *NRAS*, are small GTPases cycling between an active guanosine triphosphate (GTP)-bound and inactive guanosine diphosphate (GDP)-bound conformations. RAS proteins are tightly regulated by GTPase activating proteins (GAPs) and guanine nucleotide exchange factors (GEFs). When extracellular stimuli activates receptor tyrosine kinases (RTKs), docking sites for adaptor molecules and signal-relay proteins, such as *GRB2* and *SHP2*, are created. GEFs (e.g., SOS1) are then recruited and displace GDP from RAS allowing RAS to bind to GTP, which is abundant in the cytosol ([Fig. 1C](#f1-molce-42-441){ref-type="fig"}). GTP-bound RAS can activate a large number of effector pathways including RAF family of proteins. The mitogen-activated protein kinase (MAPK) pathway is best-characterized RAS effector pathway.

Previous studies have shown that majority of mutations found in RASopathies are not as robustly activating as those associated with human cancers which may explained by embryonic lethality resulting from the germline mutations. More recently, however, the same oncogenic somatic mutations in *HRAS* and *KRAS* are found in nevus sebaceous syndrome (NSS) suggesting that the broader involvement of RAS signaling pathway in the pathogenesis of developmental disorders ([@b27-molce-42-441]). These findings support the general perspective that the degree and duration of enhanced and/or dysregulated RAS signaling as well as cell types should be considered for its role in oncogenesis and developmental disorders. In this review, we will focus on the developmental functions of several genes associated with RASopathies including *NF1*, *PTPN11*, *SOS1*, *HRAS*, *KRAS*, *RAF1*, and *BRAF*, and their roles in the pathogenesis of RASopathies. For simplicity, we used gene sets as human gene symbols.

*NF1* AND NEUROFIBROMATOSIS TYPE I
==================================

Neurofibromatosis type I is autosomal dominant disorder caused by loss-of-function-mutations in *NF1* ([@b10-molce-42-441]). *NF1*, functions as a GAP, negatively regulates RAS pathway. Individuals with neurofibromatosis type 1 are predisposed to specific cancers, and showed neurological deficits including cognitive disability, cerebrovascular defects, malformations ([@b75-molce-42-441]). Some individuals with neurofibromatosis type 1 show brain structural abnormalities such as macrocephaly, increased white matter size, and polymicrogyria ([@b14-molce-42-441]; [@b35-molce-42-441]; [@b59-molce-42-441]). Since *NF1* is frequently associated with human cancers, initial studies have focused on its roles in cell proliferation. In 1999, Gutmann and his colleagues reported that *NF1* haploinsufficiency promotes astrocyte proliferation ([@b29-molce-42-441]). Later studies have identified the cell type- and brain region-specific function of *NF1* loss. Studies with *NF1* knockout and conditional knockout mice have been shown that depletion of *NF1* results in increased proliferation of neuroglial progenitor cells, noticeably in astrocyte and oligodendrocyte ([@b4-molce-42-441]; [@b5-molce-42-441]; [@b15-molce-42-441]). In *NF1*-deficient brains, the number of proliferative cells in the rostral migratory system, corpus callosum, cortex, striatum, and subventricular zone is higher than control at the early stage, but most of them differentiate to glial linage ([@b73-molce-42-441]). As a result, neurofibromatosis type 1 animal models showed increased gliogenesis at the expense of neurogenesis. NF1 functions through selective use of downstream RAS effectors. While MEK signaling is involved in the neuroglial progenitor proliferation, PI3K/AKT pathway is involved in neural stem cell proliferation ([@b13-molce-42-441]).

*NF1* plays a vital role in neuronal differentiation and morphology ([@b31-molce-42-441]; [@b42-molce-42-441]; [@b80-molce-42-441]). It has been reported that activation of the RAS pathway promotes neurite outgrowth ([@b3-molce-42-441]; [@b24-molce-42-441]); however, studies have shown that *NF1*-deficient neurons have shorter neurites ([@b16-molce-42-441]; [@b31-molce-42-441]). NF1 regulation of neurite outgrowth seem independent to RAS-MAPK pathway but dependent to PKA-RhoA-ROCK pathway ([@b8-molce-42-441]). The increase of gliogenesis and immature astrocyte shown in *NF1*-deficient models can explain why individuals with neurofibromatosis type 1 are susceptible to cancers in central nervous system, especially gliomas. Disrupted balance between neurogenesis and gliogenesis may also associated with other clinical manifestation related to central nervous systems.

*PTPN11* (SHP2), SOS1, RAF1 AND NOONAN SYNDROME
===============================================

Noonan syndrome is autosomal dominant disorders affecting one in 1,000 to 2,500 and characterized by distinctive facial features, short stature, chest deformity, congenital heart disease and, in some instances, neurological manifestations ([@b18-molce-42-441]; [@b57-molce-42-441]). *PTPN11* (which encodes SHP2) mutations explain nearly half of the cases, besides mutations in *SOS1*, *RAF1*, and *KRAS* ([@b63-molce-42-441]). The degree of cognitive impairment varies from person to person, but individuals with a mutation in relative upstream of RAS pathway such as *SOS1* or *PTPN11* show mild or no cognitive impairment ([@b11-molce-42-441]; [@b54-molce-42-441]). *PTPN11* mutations associated with Noonan syndrome are frequently found in the residues that are crucial for auto-inhibited closed conformation resulting elevated phosphatase activity, thus increased RAS signaling, while LEOPARD syndrome (Noonan syndrome with lentigines)-associated *PTPN11* mutants exhibit reduced catalytic activity ([@b37-molce-42-441]; [@b67-molce-42-441]). Expression of *PTPN11* mutations found in Noonan syndrome promotes neurogenesis and suppress astrogliogenesis ([@b26-molce-42-441]). Conversely, loss of *PTPN11* results in increase gliogenesis but reduce neurogenesis ([@b36-molce-42-441]; [@b81-molce-42-441]). It has been shown that *PTPN11* functions through multiple downstream signaling to control gliogenesis and neurogenesis. After rescue experiment using pSTAT3 inhibitor and MEK inhibitor, [@b26-molce-42-441] and [@b36-molce-42-441] showed that *PTPN11* inhibits astrogliogenesis through GP130-JAK-STAT3 pathway and stimulate neurogenesis through MEK-ERK pathway, and these pathways are reciprocal.

Differential regulation through selective use of downstream signaling also has been shown in oligodendrocyte development. When *PTPN11* was deleted in oligodendrocytes in ventral telencephalic region and spinal cord, the proliferation of oligodendrocyte decreased and precocious maturation observed ([@b20-molce-42-441]; [@b79-molce-42-441]). The expression of gain-of-function mutant induced to oligodendrocyte progenitor cell (OPC) proliferation with abnormal myelination ([@b20-molce-42-441]). These results suggest that *PTPN11* regulates the oligodendrocyte proliferation and maturation. Noticeably, *PTPN11* function through the MAPK-ERK pathway in OPC maturation but not important for survival and proliferation of OPC. The proliferation of OPC by *PTPN11* seems to be controlled through a different pathway such as AKT signaling ([@b22-molce-42-441]; [@b34-molce-42-441]; [@b45-molce-42-441]). *PTPN11* not only involves in neurogenesis but also promotes neuronal differentiation, neurite outgrowth and migration ([@b26-molce-42-441]; [@b32-molce-42-441]). The increased neurogenesis, abnormal myelination by gain-of-function mutation of *PTPN11* may explain why some individuals with Noonan syndrome showed neurological manifestations such as motor dysfunction and epilepsy. However, correlation between variability in cognitive dysfunction and mutated genes is not well understood.

*SOS1*, another causative gene of Noonan syndrome, is GEF of RAS ([@b12-molce-42-441]). Gain-of-function mutation of *SOS1* is usually found in patients with Noonan syndrome, and most of them are located in PH domain, which can inhibit the formation of auto-inhibitory conformation and results in the activation of RAS/MAPK pathway ([@b66-molce-42-441]; [@b68-molce-42-441]). *SOS1* mutation-positive patients with Noonan syndrome have been reported to show neurological abnormalities such as mild cognitive impairment and spinal nerve enlargement ([@b49-molce-42-441]; [@b60-molce-42-441]). However, the role of *SOS1* in the neurodevelopment process has been poorly understood. *SOS1* has been reported to be involved in neurite outgrowth by nerve growth factor (NGF) stimulation, forming RAC1/Cdc42 complex in PC12 cells ([@b1-molce-42-441]). [@b69-molce-42-441] showed that *SOS1* is highly expressed in the neonatal cortical tissue and they can activate RAS/ERK/CREB signaling by N-methyl-D-aspartate (NMDA) glutamate receptor through Shc-Grb2 interaction in neonatal cortex. Since NMDA receptor signaling is important for synaptic plasticity, the alteration of this signaling pathway can be related to cognitive delay in Noonan syndrome ([@b33-molce-42-441]). However, how Noonan syndrome-specific *SOS1* mutations affect on the neurodevelopment has not been actively studied. Considering that *SOS1* positive patients show relative better language ability and adaptive behavior in the patients with other mutations, dysregulation of *SOS1* may show relatively mild neurodevelopmental defects ([@b52-molce-42-441]; [@b51-molce-42-441]).

Gain-of-function mutation of *RAF1* is also shown in the Noonan syndrome. Most of these mutations inhibit S621 and S259 phosphorylation, which is important for closed conformation and can act as a binding site of 14-3-3 to maintain inactive state ([@b38-molce-42-441]). About 55% of *RAF1*-positive patients with Noonan syndrome showed intellectual disability, and 95% of them showed relative macrocephaly ([@b38-molce-42-441]). This indicates that *RAF1* is crucial for normal brain development; however, the function of *RAF1* in the neurodevelopment has not been actively studied. *RAF1*-deficient mice show an increase of cell proliferation and apoptotic death, and abnormal differentiation in the hippocampus ([@b50-molce-42-441]). This may be related to cognitive impairment in Noonan syndrome.

*HRAS* AND COSTELLO AND NEVUS SEBACEOUS SYNDROMES
=================================================

Costello syndrome is an autosomal dominant disorder caused by germline mutation of *HRAS* ([@b2-molce-42-441]). The typical symptoms are severe failure to thrive, cardiac abnormalities, papilloma, and malignant tumors, short stature, hyperkeratinosis and neurological abnormalities including hypotonia, macrocephaly, developmental delay, and intellectual disability ([@b2-molce-42-441]; [@b54-molce-42-441]; [@b65-molce-42-441]). Some individuals with Costello syndrome show brain structural abnormalities such as poor grey-white matter differentiation, small corpus callosum and small brain stem ([@b17-molce-42-441]). The *HRAS* mutations occurred in Costello syndrome located in glycine 12 and glycine 13, the frequent oncogenic gain-of-function mutations activating RAS-MAPK pathway ([@b2-molce-42-441]).

*HRAS* plays crucial functions during brain development. *HRAS* promotes proliferation of neural stem cells and involved in neuronal morphological development. Induced pluripotent stem cells (iPSCs) derived from Costello syndrome showed increased production of cortical neurons associated with extended progenitor phase ([@b58-molce-42-441]). Transgenic mice with *HRAS* gain-of-function mutation show aberrant cortical lamination and abnormal neuronal morphology such as cytomegaly and short neurite length ([@b58-molce-42-441]). *HRAS* activation after postnatal stage also leads to neuronal hypertrophy and more complex dendritic structure and enlarged axons ([@b25-molce-42-441]; [@b64-molce-42-441]). Another study showed that *HRAS* localize to axon growth cone with PI3K during the formation of axon ([@b21-molce-42-441]). *HRAS* also regulates the astrogliogenesis. During transition from neurogenesis to gliogenesis, [@b47-molce-42-441] showed that variants found in Costello syndrome suppress neurogenesis but promote astrogenesis. Increased astrogenesis is further maintained at the postnatal stage. Noticeably, astrocyte-specific expression of *HRAS* gain-of-function mutation could influence neuronal morphogenesis by extracellular component ([@b40-molce-42-441]). These studies suggest non-cell autonomous effects caused by *HRAS* somatic gain-of-function mutation during the brain development.

Somatic mutations of *HRAS* and *KRAS* in the same loci are also found in a group of neurocutaneous disease called NSS which is characterized by sebaceous nevus associated with other abnormalities in brain, eyes and bones ([@b27-molce-42-441]). Interestingly, the mutations were predominantly found in lesions and associated secondary tumors but not in nonlesional tissues. Studying the function of the oncogenic *HRAS* and *KRAS* mutations in developing brain may provide patho-developmental mechanisms of NSS.

*KRAS, BRAF, MEK1, MEK2* AND CARDIO-FACIO-CUTANEOUS SYNDROME
============================================================

Cardio-facio-cutaneous syndrome is dominant congenital disorder typically characterized by distinctive facial appearance, heart defects and intellectual disability, short stature and skin abnormalities ([@b46-molce-42-441]). *KRAS* mutations are found in Cardio-facio-cutaneous syndrome and Noonan syndrome. Somatic mutations of *KRAS* also found in NSS ([@b27-molce-42-441]). However, the location of germline and somatic mutations are distinct in pattern. Oncogenic gain-of-function mutations are frequently found in NSS while more functionally mild mutations are identified in Noonan and cardio-facio-cutaneous syndromes ([@b27-molce-42-441]; [@b63-molce-42-441]; [@b62-molce-42-441]). This may explained by embryonic lethality due to strong germline gain-of-function mutations ([@b71-molce-42-441]). Unlike to *NF1*, *PTPN11*, and *HRAS*, function of *KRAS* have not been well studied in the neurodevelopment. [@b41-molce-42-441] has been shown that activation of *KRAS* is required for self-renewal of iPSC. In their study, *KRAS* activation by p.G13C heterozygote mutation suppresses neuronal differentiation suggesting its role during the neurodevelopment. *KRAS* activation but not *HRAS* and *NRAS* increases neural stem cell proliferation and astrogliogenesis in consistent with *NF1* studies ([@b6-molce-42-441]).

Besides *KRAS*, mutations in *BRAF*, *MAP2K1* (*MEK1*), and *MAP2K2* (*MEK2*) also found in cardio-facio-cutaneous syndrome. The most frequently mutated gene is *BRAF*, accounting for 75% of mutation-positive cases ([@b54-molce-42-441]). Most of these mutations have shown to activate RAS pathway; however, some of them showed impaired kinase activity ([@b56-molce-42-441]). Also, *BRAF* mutations found in cardio-facio-cutaneous syndrome are frequently located in the cysteine-rich domain or protein kinase domain while mutations found in cancers are located in catalytic domain ([@b54-molce-42-441]; [@b61-molce-42-441]). Like other RAS pathway components, *BRAF* plays important roles in neurodevelopmental processes. Firstly, *BRAF* is essential for maintenance of neural progenitor pool and proliferation of neural stem cells ([@b9-molce-42-441]). Patient-derived neural stem cells carrying *BRAF* p.Q257R mutation showed premature neural differentiation resulting rapid depletion of neural progenitor pool ([@b76-molce-42-441]). Since many subtypes of cells are derived from neural progenitor cells in highly sophisticated spatiotemporal order ([@b30-molce-42-441]; [@b48-molce-42-441]) ([Fig. 1A](#f1-molce-42-441){ref-type="fig"}), depletion of neural progenitor pools can lead to the imbalance of neuronal and glial cells. *BRAF* is also involved in the neuronal development such as survival, migration, differentiation and maturation. *BRAF* promotes neuronal survival by reducing cAMP-mediated *Raf-1* (*C-raf*) inhibition and activating MEK ([@b19-molce-42-441]). Also, it promotes the survival of motor neuron and sensory neuron ([@b74-molce-42-441]). Unlike other RAF proteins, *BRAF* activity is critical for neuronal migration. When *B-raf* is substituted by *A-raf*, cortical upper layer neurons cannot migrate to cortical plate. Similarly, constitutive activation of *BRAF* leads to abnormal cortical lamination ([@b39-molce-42-441]). Studies with knockout mice have shown that RAF activity, especially *RAF1* and *BRAF*, is essential for neuronal maturation and axon projection ([@b78-molce-42-441]). It has been speculated that RAF activity over a certain level is required for normal neuronal development. Besides promoting gliogenesis, *BRAF* signaling function as a positive regulator of astrocyte proliferation. Using strong gain-of-function mutation of *BRAF* (human V600E, mouse V637E), it has been shown that BRAF activation during embryonic stage increase proliferation of glial lineage cells in cortex and spinal cord ([@b39-molce-42-441]; [@b44-molce-42-441]; [@b70-molce-42-441]). *BRAF* activation at the adult stage also showed hyper-proliferation of astrocyte leading to astrocytoma ([@b28-molce-42-441]). Similarly, *RAF1* also promotes astrocyte proliferation in an autocrine/paracrine manner *in vitro* ([@b55-molce-42-441]).

*BRAF* also stimulates the oligodendrocyte maturation and differentiation. When *BRAF* is ablated, oligodendrocyte maturation is impaired ([@b23-molce-42-441]). They suggested that *BRAF* induce the oligodendrocyte differentiation and myelination by forming a complex with downstream MAPK-ERK components, and *BRAF* can act as a rate-limiting activator. This result is concordant with previous findings that MAPK-ERK pathway plays important roles for oligodendrocyte maturation ([@b22-molce-42-441]; [@b34-molce-42-441]). Developmental defects in oligodendrocyte associated with BRAF mutations may explain some clinical manifestation such as thin corpus callosum and reduction of white matter volume ([@b77-molce-42-441]). A strong gain-of-function mutation of *BRAF* may associated with epilepsy ([@b39-molce-42-441]; [@b53-molce-42-441]; [@b72-molce-42-441]). [@b39-molce-42-441] reported that constitutive activation of *BRAF* can lead to a morphological change of neuron and epileptogenesis. [@b76-molce-42-441] also reported that neuronal precursor cells derived from cardio-facio-cutaneous syndrome patients with *BRAF* p.Q257R produce the neurons with high intrinsic excitability. *BRAF* participates in the various step of neurodevelopment processes such as maintenance of neural progenitor pool, fate specification, gliogenesis, and oligodendrocyte differentiation ([Fig. 1B](#f1-molce-42-441){ref-type="fig"}). However, most studies have focused on neurodevelopmental defects caused by ablation of *BRAF* or strong activation found in human cancers. Thus, how these findings are related to cardio-facio-cutaneous syndrome should be addressed more carefully.

CONCLUSION REMARK
=================

The shared neurodevelopmental aspect of RAS-MAPK pathway activation is the enhanced proliferation of neural stem cell leading to hyper-proliferation and expansion of glial lineage cells. The imbalance of neuro-glial cellular subtypes during the brain development explains some neurological manifestations seen in RASopathies. Developmental defects in brain may associated with neurocognitive deficit as well as structural brain defects. As evident in oligodendrocyte development, cell type- and brain region-specific functions of RAS pathway components may explain diversity of clinical spectrum among RASopathies, especially clinical features related to myelination, white matter volume, and corpus callosum. Other developmental defects such as neuronal migration and neuronal morphology defect may also explain the structural brain defects and disrupted circuit formation affecting neurocognitive functions. Further studies would find detailed cellular and molecular mechanisms underlying clinical manifestations and its roots during neurodevelopment. Revealing these mechanisms would help to treat or to delay the progression of RASopathies at the earliest point as possible.
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(A) The simplified view of the corticogenesis. For more detail information, refer to [@b30-molce-42-441]; [@b48-molce-42-441]. The neurodevelopmental process progresses from left to right. Neuronal differentiation, proliferation of glial lineage cells, and oligodendrocyte differentiation and myelination occur at the same time in different cell types. (B) The role of components in the RAS/MAPK pathway in neurodevelopmental process. Each column is listed in the chronological order roughly, matching with Figure 1A. Red represents that the corresponding proteins promotes the step of column, in contrast, green means that the corresponding proteins suppresses the step of column. Gray indicates that the relationship of gene and each step is unknown. Yellow indicates that the genes are involved in each step, but it is uncertain that those genes promote or suppress the process. Of note, NF1 is a negative regulator of RAS/MAPK pathway, unlike the other genes. (C) The RAS/MAPK pathway and the disorders involving somatic/germline mutations of related genes. RTK, receptor tyrosine kinase; Nf1, neurofibromatosis type 1.](molce-42-441f1){#f1-molce-42-441}
